Improved formulation for administration of steroid compounds

Details Improved formulation for administration of steroid compounds Improved formulation for administration of steroid compounds

A - Human Necessities

61

K

A61K 31/565 (2006.01) A61K 47/40 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2237023

Improved cyclodextrin formulations for the administration of 5 .beta. steroids including a etiocholanolone, .beta. etiocholonolone, and etiocholandione are provided. Also provided are cyclodextrin formulations including at least one of the 5 .beta. steroids and DHEA. The formulations are suitable for parenteral administration, particularly intravenous administration and are also suitable for treating a condition which responds to treatment with the 5 .beta. steroids alone or together with DHEA, particularly where it is desired to decrease the amount of DHEA administered, including such conditions as obesity, diabetes syndrome, diabetes-associated hypercorticoidism or combinations thereof, anemic disorders including but not limited to aplastic anemia and anemia associated with renal failure or chemotherapy-induced or radiation-induced anemia or neutropenia, and autoimmune or inflammatory disorders such as lupus erythematosus.

L'invention concerne des formulations cyclodextriniques pour l'administration de 5 beta stéroïdes dont alpha étiocholonolone, beta étiocholonolone et étiocholandione. Elle porte également sur des formulations cyclodextriniques comprenant au moins un des 5 beta stéroïdes et de la déshydroépiandostérone (DHEA). Lesdites formulations conviennent à l'administration parentérale, en particulier l'administration par voie intraveineuse et également au traitement d'un état qui répond au traitement aux 5 beta stéroïdes seuls ou conjointement avec DHEA, en particulier lorsque l'on désire réduire la quantité de DHEA administrée. Ces états comprennent l'obésité, le syndrome diabétique, l'hypercorticoïdisme associé au diabète ou leur combinaison, des troubles anémiques dont, entre autres, l'anémie aplasique et la neutropénie ou l'anémie associée à une insuffisance rénale ou induite par une chimiothérapie ou les rayons, les troubles autoimmuns ou inflammatoires tels que le lupus érythémateux.

Affiliated with

Also associated with

Rating

Improved formulation for administration of steroid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Improved formulation for administration of steroid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved formulation for administration of steroid compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1522200